AU2016267142B2 - Tumor biomarkers and use thereof - Google Patents

Tumor biomarkers and use thereof Download PDF

Info

Publication number
AU2016267142B2
AU2016267142B2 AU2016267142A AU2016267142A AU2016267142B2 AU 2016267142 B2 AU2016267142 B2 AU 2016267142B2 AU 2016267142 A AU2016267142 A AU 2016267142A AU 2016267142 A AU2016267142 A AU 2016267142A AU 2016267142 B2 AU2016267142 B2 AU 2016267142B2
Authority
AU
Australia
Prior art keywords
methylpyridin
amine
naphthyridin
methyl
benzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016267142A
Other languages
English (en)
Other versions
AU2016267142A1 (en
Inventor
Songzhu An
Tao Huang
Xiaoli Qin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Curegenix Corp
Original Assignee
Curegenix Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curegenix Corp filed Critical Curegenix Corp
Publication of AU2016267142A1 publication Critical patent/AU2016267142A1/en
Application granted granted Critical
Publication of AU2016267142B2 publication Critical patent/AU2016267142B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2016267142A 2015-05-26 2016-05-26 Tumor biomarkers and use thereof Ceased AU2016267142B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562166305P 2015-05-26 2015-05-26
US62/166,305 2015-05-26
PCT/US2016/034245 WO2016191525A1 (en) 2015-05-26 2016-05-26 Tumor biomarkers and use thereof

Publications (2)

Publication Number Publication Date
AU2016267142A1 AU2016267142A1 (en) 2017-11-30
AU2016267142B2 true AU2016267142B2 (en) 2020-12-24

Family

ID=57394192

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016267142A Ceased AU2016267142B2 (en) 2015-05-26 2016-05-26 Tumor biomarkers and use thereof

Country Status (9)

Country Link
US (2) US20180112273A1 (enExample)
EP (1) EP3302479A4 (enExample)
JP (2) JP2018522062A (enExample)
KR (1) KR20180010198A (enExample)
CN (1) CN107708699A (enExample)
AU (1) AU2016267142B2 (enExample)
CA (1) CA2985813A1 (enExample)
HK (1) HK1251171A1 (enExample)
WO (1) WO2016191525A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2968348A4 (en) 2013-03-12 2016-11-09 Curegenix Inc COMPOUNDS FOR THE TREATMENT OF CANCER
US20200306244A1 (en) * 2016-06-22 2020-10-01 Novartis Ag Wnt inhibitors for use in the treatment of fibrosis
CN118497323A (zh) * 2016-12-21 2024-08-16 新加坡科技研究局 用于鉴定恶性肿瘤的试剂盒及其用途
CN107441045B (zh) 2017-07-21 2018-10-19 广州源生医药科技有限公司 用于递送Wnt信号通路抑制剂的脂质体制剂及其制备方法
CN108685923A (zh) * 2018-06-07 2018-10-23 广州源生医药科技有限公司 Wnt信号通路抑制剂在治疗LGR5阳性癌症中的应用
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013130364A1 (en) * 2012-02-28 2013-09-06 Novartis Ag Cancer patient selection for administration of wnt signaling inhibitors using rnf43 mutation status
WO2014165232A1 (en) * 2013-03-12 2014-10-09 Curegenix, Inc. Compounds for treatment of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA103918C2 (en) * 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
UY33469A (es) * 2010-06-29 2012-01-31 Irm Llc Y Novartis Ag Composiciones y metodos para modular la via de señalizacion de wnt
CN102558173B (zh) * 2010-12-31 2015-05-20 广州源生医药科技有限公司 抑制wnt信号传导的化合物、组合物及其应用
RU2014133069A (ru) * 2012-02-11 2016-04-10 Дженентек, Инк. Транслокации r-спондина и способы с их использованием
BR112016008477A2 (pt) * 2013-10-18 2017-10-03 Genentech Inc Corpos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica e usos do anticorpo

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013130364A1 (en) * 2012-02-28 2013-09-06 Novartis Ag Cancer patient selection for administration of wnt signaling inhibitors using rnf43 mutation status
WO2014165232A1 (en) * 2013-03-12 2014-10-09 Curegenix, Inc. Compounds for treatment of cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J. LIU ET AL, "Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, (2013-11-25), vol. 110, no. 50, doi:10.1073/pnas.1314239110, ISSN 0027-8424, pages 20224 - 20229 *
SOMASEKAR SESHAGIRI ET AL, "Recurrent R-spondin fusions in colon cancer", NATURE, (2012-01-01), vol. 488, no. 7413, doi:10.1038/nature11282, ISSN 0028-0836, pages 660 - 664 *

Also Published As

Publication number Publication date
AU2016267142A1 (en) 2017-11-30
JP2021130694A (ja) 2021-09-09
JP2018522062A (ja) 2018-08-09
US20180112273A1 (en) 2018-04-26
EP3302479A1 (en) 2018-04-11
HK1251171A1 (zh) 2019-01-25
CA2985813A1 (en) 2016-12-01
WO2016191525A1 (en) 2016-12-01
EP3302479A4 (en) 2019-01-09
US20210054466A1 (en) 2021-02-25
CN107708699A (zh) 2018-02-16
KR20180010198A (ko) 2018-01-30

Similar Documents

Publication Publication Date Title
US10660889B2 (en) Compounds for treatment of cancer
US20210054466A1 (en) Tumor biomarkers and use thereof
AU2016341445B2 (en) 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases
US10087181B2 (en) Compound as WNT signaling inhibitor, composition, and use thereof
JP2023540270A (ja) 複素環式化合物およびその使用
BR112021008741A2 (pt) compostos bicíclicos
TW202104189A (zh) 雙環化合物
CA3068854A1 (en) Selective inhibitors of clinically important mutants of the egfr tyrosine kinase
IL234052A (en) Derivatives of 2-amino, 6-phenyl-conjugated pyrrolo [3,2-d] pyrimidine are useful as inhibitors of kinase raf
KR20110079887A (ko) 피라졸로피리미딘 ｊａｋ 억제제 화합물 및 방법
CN116406271A (zh) 双环类化合物
KR20140047160A (ko) 인다졸 화합물, 조성물 및 사용 방법
CN107531683B (zh) Usp7抑制剂化合物及使用方法
CN106232118A (zh) 杂芳族化合物及其作为多巴胺d1配体的用途
WO2018214866A9 (zh) 一种氮杂芳基衍生物、其制备方法和在药学上的应用
CN116568671A (zh) 杂环Cullin-RING泛素连接酶化合物及其用途
EP3134405A1 (en) Heteroaromatic compounds and their use as dopamine d1 ligands
WO2023036252A1 (zh) 吡咯并嘧啶类或吡咯并吡啶类衍生物及其医药用途
WO2025059366A1 (en) Ras inhibitors
HK1161529B (en) Pyrazolopyrimidine jak inhibitor compounds and methods

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired